{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T02:06:10Z","timestamp":1747188370826,"version":"3.40.5"},"reference-count":23,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Severe acute respiratory syndrome coronavirus\u20102 (SARS\u2010CoV\u20102)\u2010infected patients exhibit disease ranging from asymptomatic to severe pneumonia, multi\u2010organ failure, and death. convalescent COVID plasma (CCP) from recovered patients with high levels of neutralizing antibodies has demonstrated therapeutic efficacy to reduce the morbidity of coronavirus disease 2019 (COVID\u201019) in some studies. The development of assays to characterize the activity of CCP to neutralize SARS\u2010CoV\u20102 infectivity offers the possibility to improve potential therapeutic efficacy. Lyophilization of CCP may increase the availability of this therapy. We hypothesized that SARS\u2010CoV\u20102 antibody profiles of pooled lyophilized pathogen\u2010reduced CCP from COVID\u201019\u2010recovered blood donors retains virus\u2010neutralizing efficacy as reported for frozen pathogen\u2010reduced CCP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Pooled lyophilized pathogen\u2010reduced plasma was prepared from recovered COVID plasma donors. Antibodies to SARS\u2010CoV\u20102 were characterized in each donor plasma prior to pathogen reduction and lyophilization and after lyophilization of individual CCP, and in the lyophilized CCP pool. Several complimentary assays were used to characterize antibody levels, neutralizing capacity, and the spectrum of antigen reactivity. The mean values for individual plasma samples and the value in the pool were compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean ratio for antibody binding to SARS\u2010CoV\u20102 antigens before and after treatment was 0.95\u2009\u00b1\u20090.22 mean fluorescent intensity (MFI) units. Antibody activity to an array of influenza virus antigens demonstrated a mean activity ratio of 0.92\u2009\u00b1\u20090.12 MFI before and after treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The antibody activity in pooled pathogen\u2010reduced lyophilized CCPs demonstrated minimal impact due to pathogen reduction treatment and lyophilization.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.17506","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T11:41:36Z","timestamp":1692877296000},"page":"1633-1638","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of antibodies to <scp>SARS\u2010CoV<\/scp>\u20102 in lyophilized plasma prepared with amotosalen\u2010<scp>UVA<\/scp> pathogen reduction"],"prefix":"10.1111","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-4699","authenticated-orcid":false,"given":"Christophe","family":"Martinaud","sequence":"first","affiliation":[{"name":"Blood Donation Screening Laboratory French Military Blood Institute  Clamart France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9679-1211","authenticated-orcid":false,"given":"Anil","family":"Bagri","sequence":"additional","affiliation":[{"name":"Cerus Corporation  Concord California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng\u2010Ting","family":"Tsai","sequence":"additional","affiliation":[{"name":"ENable Biosciences Inc  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael R.","family":"de Assis","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, School of Medicine University of California Irvine  Irvine California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Gatmaitan","sequence":"additional","affiliation":[{"name":"Cerus Corporation  Concord California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter V.","family":"Robinson","sequence":"additional","affiliation":[{"name":"ENable Biosciences Inc  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Seftel","sequence":"additional","affiliation":[{"name":"ENable Biosciences Inc  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saahir","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine University of California Irvine Health  Orange California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip L.","family":"Felgner","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biophysics, School of Medicine University of California Irvine  Irvine California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-9869","authenticated-orcid":false,"given":"Laurence M.","family":"Corash","sequence":"additional","affiliation":[{"name":"Cerus Corporation  Concord California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25793"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008423"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031893"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119657"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.261784"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033700"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17083"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2022.100901"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16819"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1079"},{"key":"e_1_2_7_13_1","first-page":"1761","article-title":"Use of freeze\u2010dried plasma in French intensive care unit in Afghanistan","volume":"71","author":"Martinaud C","year":"2011","journal-title":"J Trauma"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3182608cdd"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(20)30037-9"},{"key":"e_1_2_7_16_1","first-page":"206","article-title":"Preservation of anti\u2010SARS\u2010CoV\u20102 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light","volume":"20","author":"Larrea L","year":"2022","journal-title":"Blood Transfus"},{"key":"e_1_2_7_17_1","first-page":"1","article-title":"COVID\u201019 repeated convalescent plasma collection: analysis of 149 donations from 88 French military health workers","volume":"395","author":"Conan PL","year":"2021","journal-title":"Transfus Med Hemother"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31796-1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20095-2"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/usaa347"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16772"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac358"},{"key":"e_1_2_7_23_1","first-page":"1707","article-title":"Highly potent SARS\u2010CoV\u20102 neutralization by intravenous immunoglobulins manufactured from post\u2010COVID\u201019 and COVID\u201019\u2010vaccinated plasma donations","volume":"224","author":"Karbiener M","year":"2021","journal-title":"J Infect Dis"},{"volume-title":"Considerations for the development of dried plasma products intended for transfusion: draft guidance for industry","year":"2018","author":"U.S. Food and Drug Administration","key":"e_1_2_7_24_1"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.17506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T05:18:23Z","timestamp":1694582303000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.17506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/trf.17506"],"URL":"https:\/\/doi.org\/10.1111\/trf.17506","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"type":"print","value":"0041-1132"},{"type":"electronic","value":"1537-2995"}],"subject":[],"published":{"date-parts":[[2023,8,24]]},"assertion":[{"value":"2023-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}